Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Kamada
(NASDAQ:KMDA)
Intraday
$4.95
-0.13
[-2.56%]
After-Hours
$4.95
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$4.95
-0.13
[-2.56%]
At close: Apr 17
$4.95
0
[0.00%]
After Hours: 8:45AM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Kamada Stock (NASDAQ:KMDA)
Kamada Stock (NASDAQ: KMDA)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, March 07, 2024
HC Wainwright & Co. Reiterates Buy on Kamada, Maintains $11 Price Target
Benzinga Newsdesk
-
Mar 7, 2024, 7:35AM
Wednesday, March 06, 2024
Kamada Expects 2024 Revenues Of $156M-$160M Vs. $166.14M Consensus, And Sees Adjusted EBITDA In The Range Of $27M-$30M
Benzinga Newsdesk
-
Mar 6, 2024, 7:07AM
Kamada Q4 EPS $0.09 Beats $0.05 Estimate, Sales $36.43M Miss $37.71M Estimate
Benzinga Newsdesk
-
Mar 6, 2024, 7:03AM
Earnings Scheduled For March 6, 2024
Benzinga Insights
-
Mar 6, 2024, 5:00AM
Tuesday, March 05, 2024
Preview: Kamada's Earnings
Benzinga Insights
-
Mar 5, 2024, 2:02PM
Thursday, December 07, 2023
Kedrion Announces An Eight-Year Extension Of The Distribution Agreement With Kamada In The U.S. For Kedrab
Benzinga Newsdesk
-
Dec 7, 2023, 11:02AM
Wednesday, December 06, 2023
Kamada shares are trading higher after the company announced a binding memorandum of understanding with Kedrion for the amendment and extension of the KEDRAB U.S. distribution agreement between the parties.
Benzinga Newsdesk
-
Dec 6, 2023, 12:07PM
Kamada Announces Binding MOU With Kedrion For The Amendment And Extension Of US Distribution Agreement For KEDRAB; Within First Four Years, Kedrion Will Purchase Minimum Quantities Of KEDRAB With Revenues To Kamada Of $180M
Benzinga Newsdesk
-
Dec 6, 2023, 7:03AM
Tuesday, November 14, 2023
HC Wainwright & Co. Reiterates Buy on Kamada, Maintains $11 Price Target
Benzinga Newsdesk
-
Nov 14, 2023, 7:00AM
Monday, November 13, 2023
Kamada Q3 EPS $0.06 Beats $0.03 Estimate, Sales $37.93M Beat $37.54M Estimate
Benzinga Newsdesk
-
Nov 13, 2023, 7:04AM
Earnings Scheduled For November 13, 2023
Benzinga Insights
-
Nov 13, 2023, 6:40AM
Monday, October 16, 2023
Kamada Announced Multiple Recent Achievements Related To Cytogam, Indicated For The Prophylaxis Of Cytomegalovirus Disease Associated With Transplantation Of Kidney, Lung, Liver, Pancreas, And Heart
Benzinga Newsdesk
-
Oct 16, 2023, 7:25AM
Monday, October 09, 2023
Why ParaZero Technologies Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin
-
Oct 9, 2023, 1:30PM
Wednesday, August 30, 2023
Kamada Announces Shareholder Approval And Planned Closing Of $60M Private Placement With FIMI Opportunity Funds
Benzinga Newsdesk
-
Aug 30, 2023, 7:01AM
Thursday, August 17, 2023
HC Wainwright & Co. Reiterates Buy on Kamada, Maintains $11 Price Target
Benzinga Newsdesk
-
Aug 17, 2023, 6:13AM
Wednesday, August 16, 2023
Kamada Reiterates Full-Year 2023 Revenue Guidance Of $138M-$146M (Est. $141.36M) And Adjusted EBITDA Of $22M-$26M
Benzinga Newsdesk
-
Aug 16, 2023, 7:11AM
Kamada Q2 EPS $0.04 Beats $0.02 Estimate, Sales $37.44M Beat $34.17M Estimate
Benzinga Newsdesk
-
Aug 16, 2023, 7:09AM
Earnings Scheduled For August 16, 2023
Benzinga Insights
-
Aug 16, 2023, 6:02AM
Tuesday, August 15, 2023
Kamada Earnings Preview
Benzinga Insights
-
Aug 15, 2023, 11:00AM
Wednesday, July 12, 2023
Kamada Announces Kedrion Exercised its Option for Two-Year Extension of KEDRAB Distribution Agreement in the US
Benzinga Newsdesk
-
Jul 12, 2023, 7:08AM
Friday, May 26, 2023
Watching Kamada Ltd; Zacks Small-Cap Research Sets $14 Price Valuation; Says This Model Is Highly Dependent Upon Continued Commercial Success Of The Company's Products And Will Be Adjusted Accordingly Based On Future Results
Happy Mohamed
-
May 26, 2023, 10:59AM
Thursday, May 25, 2023
HC Wainwright & Co. Reiterates Buy on Kamada, Maintains $11 Price Target
Benzinga Newsdesk
-
May 25, 2023, 6:10AM
Wednesday, May 24, 2023
Why America's Car-Mart Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin
-
May 24, 2023, 12:48PM
Abercrombie & Fitch, Urban Outfitters, Photronics And Other Big Stocks Moving Higher On Wednesday
Lisa Levin
-
May 24, 2023, 10:41AM
Kamada shares are trading higher after the company reported better-than-expected EPS results and announced a $60 million private placement with FIMI Opportunity Funds.
Benzinga Newsdesk
-
May 24, 2023, 10:05AM
Earnings Scheduled For May 24, 2023
Benzinga Insights
-
May 24, 2023, 8:24AM
Kamada: Q1 Earnings Insights
Benzinga Insights
-
May 24, 2023, 7:20AM
Kamada Q1 EPS $0.04 Beats $0.02 Estimate, Sales $30.71M Miss $34.30M Estimate
Benzinga Newsdesk
-
May 24, 2023, 7:15AM
Kamada Announces A $60M Private Placement With FIMI Opportunity Funds
Benzinga Newsdesk
-
May 24, 2023, 7:07AM
Kamada Announces $60M Private Placement With FIMI Opportunity Funds
Benzinga Newsdesk
-
May 24, 2023, 7:05AM
Tuesday, May 23, 2023
Kamada Earnings Preview
Benzinga Insights
-
May 23, 2023, 1:00PM
Wednesday, May 17, 2023
Earnings Scheduled For May 17, 2023
Benzinga Insights
-
May 17, 2023, 8:06AM
Tuesday, May 16, 2023
Kamada Earnings Preview
Benzinga Insights
-
May 16, 2023, 12:01PM
Kamada Announces Receipt Of Marketing Authorization For Glassia For Treatment Of Alpha-1 Antitrypsin Deficiency In Switzerland
Benzinga Newsdesk
-
May 16, 2023, 7:05AM
Thursday, March 16, 2023
HC Wainwright & Co. Reiterates Buy on Kamada, Maintains $11 Price Target
Benzinga Newsdesk
-
Mar 16, 2023, 6:20AM
Wednesday, March 15, 2023
Kamada Expects FY23 Revenues Of $138M-$146M Vs. Consensus Of $147.21M
Benzinga Newsdesk
-
Mar 15, 2023, 7:09AM
Kamada Q4 EPS $0.07 Beats $0.06 Estimate, Sales $45.44M Beat $44.64M Estimate
Benzinga Newsdesk
-
Mar 15, 2023, 7:04AM
Earnings Scheduled For March 15, 2023
Benzinga Insights
-
Mar 15, 2023, 4:41AM
Tuesday, March 14, 2023
Earnings Outlook For Kamada
Benzinga Insights
-
Mar 14, 2023, 1:02PM
Monday, February 13, 2023
Watching Kamada; Zacks Small-Cap Research Sets $14 Valuation
Benzinga Newsdesk
-
Feb 13, 2023, 9:53AM
Wednesday, January 04, 2023
Kamada Announces Submission Of Application To US FDA To Manufacture CYTOGAM At Company's Facility In Israel
Benzinga Newsdesk
-
Jan 4, 2023, 7:01AM
Thursday, December 15, 2022
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Dec 15, 2022, 11:19AM
Wednesday, November 23, 2022
Acucort Signs Its First Commercial Agreement For The Company's Drug Zeqmelit
Benzinga Newsdesk
-
Nov 23, 2022, 10:59AM
Tuesday, November 22, 2022
Kamada Reiterates FY2022 Sales Of $125M-$135M, Up 20%-30% YoY Vs. Consensus Of $83.67M
Benzinga Newsdesk
-
Nov 22, 2022, 7:05AM
Kamada Q3 Adjusted EPS $0.10, Sales $32.22M Beat $29.76M Estimate
Benzinga Newsdesk
-
Nov 22, 2022, 7:03AM
Earnings Scheduled For November 22, 2022
Benzinga Insights
-
Nov 22, 2022, 5:21AM
Monday, November 21, 2022
Kamada's Earnings: A Preview
Benzinga Insights
-
Nov 21, 2022, 9:04AM
Monday, November 07, 2022
Kamada Provides Update On Phase 3 Clinical Trial Of Inhaled AAT; Says 30 PAtients Enrolled To Date, DSMB Recommends Study Continuation Without Modification
Benzinga Newsdesk
-
Nov 7, 2022, 7:10AM
Wednesday, August 17, 2022
Kamada: Q2 Earnings Insights
Benzinga Insights
-
Aug 17, 2022, 7:45AM
Kamada Maintains FY22 Sales Guidance Range Of $125M-$135M
Benzinga Newsdesk
-
Aug 17, 2022, 7:02AM
Show more